权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma

项目 3：AMPK 自噬途径作为胰腺导管腺癌的代谢负担

基本信息

批准号：
10629065
负责人：
Reuben Shaw
金额：
$ 46.68万
依托单位：
SALK INSTITUTE FOR BIOLOGICAL STUDIES
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-06 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10629065
关键词：
Address Adenocarcinoma Affect Alanine Attenuated Automobile Driving Autophagocytosis Autophagosome Biochemical Biological Availability Cell Compartmentation Cell Nucleus Cell Survival Cell physiology Cells Characteristics Chemoresistance Chloroquine Clinic Clinical Collaborations DNA Damage Desmoplastic Development Disease Disease Progression Duct (organ) structure Enzymes Epigenetic Process Epithelial Cells Epithelium FRAP1 gene Fibroblasts Gene Expression Genetic Genetic Transcription Genetically Engineered Mouse Growth HDAC3 gene Histone Deacetylase Human KPC model Knowledge Lesion MEK inhibition MEKs Malignant Neoplasms Malignant neoplasm of pancreas Measures Mediating Mediator Metabolic Metabolic stress Metabolism Modality Mus Mutation Myelogenous Normal Cell Nutrient Nutrient availability Organelles Organoids Pancreas Transplantation Pancreatic Ductal Adenocarcinoma Paracrine Communication Pathway interactions Performance Pharmaceutical Preparations Phenotype Phosphorylation Phosphotransferases Population Proteins Recycling Regulation Reporter Reporting Research Resistance Role Signal Transduction Source Stress Stromal Cells Therapeutic Toxic effect Translating Up-Regulation Vascularization Work Xenograft procedure antagonist checkpoint inhibition chemotherapy defined contribution effective therapy efficacy evaluation epigenetic regulation experimental study in vivo inhibition of autophagy inhibitor kinase inhibitor mTOR inhibition mouse model neoplastic cell novel novel strategies pancreatic ductal adenocarcinoma model pancreatic neoplasm pharmacologic programs response synergism targeted treatment therapeutic target therapy resistant tool transcriptional reprogramming treatment response treatment strategy tumor tumor growth tumor microenvironment tumor progression

项目摘要

PROJECT SUMMARY – Project 3: Autophagy Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest forms of cancer with few effective therapies. The poor performance of current treatments is partly due to metabolic adaptations in both the tumor and stromal compartments, such as the recycling of proteins and organelles through increased autophagy. As a hallmark of PDA, autophagy provides a key source of nutrients in the restrictive tumor microenvironment (TME). Accumulating evidence also implicates the autophagy program as a critical mediator of resistance to numerous therapeutics, including chemotherapy, MEK inhibitors, and immune checkpoint inhibition. Foundational research from the Shaw group decoded key biochemical steps involved in the initiation of autophagy, including upstream regulation of AMPK and its downstream activation of ULK1 and ULK2, the kinases that drive autophagosome formation. More recent work from the Shaw group has also revealed that AMPK can block the translocation of Class II HDACs to the nucleus. Despites these advances, the specific roles of AMPK in autophagy control and epigenetic regulation have never been investigated in pancreatic cancer. Moreover, while autophagy has emerged as an attractive therapeutic target in pancreatic cancer, efforts to translate this to the clinic have been hindered by a lack of autophagy-specific inhibitors, with only broad lysosomotropic agents like chloroquine available for study. To address this gap, the lab has developed novel, bioavailable inhibitors of ULK1 and ULK2, two of only three druggable enzymes specific to the autophagy pathway. These inhibitors provide critical tools with which to dissect the contributions of autophagy to PDA growth and form the basis for a new approach for overcoming therapeutic resistance in this deadly disease. Here, experiments proposed in Aim 1 will define when and where different facets of AMPK signaling and autophagy are activated during disease progression in the autochthonous mouse KPC model of PDA. In collaboration with Project 1, conditional deletions of AMPK or its downstream targets ULK1/2 and HDAC3 will be used to evaluate their contribution to metabolic adaptations driving tumor growth and epigenetic changes mediating tumor cellular functions. In addition, the contribution of AMPK pathway components in supporting PDA resistance to chemotherapeutics and targeted therapies will be dissected. In Aim 2, the roles of canonical and noncanonical autophagy in non-cell autonomous support of pancreatic tumor growth will be delineated by comparing stromal deletion of ULK1/2 and ATG7. In addition, experiments will dissect cell-specific requirements for autophagy within the fibroblast and myeloid compartments in supporting PDA therapeutic resistance. In Aim 3, the Shaw lab’s novel, bioavailable ULK inhibitor will be used to determine how selective inhibition of autophagy impacts PDA growth through reprogrammed tumor and stromal cell function. The potential of ULK inhibitors in rescuing autophagy-dependent therapeutic resistance to chemotherapies, MEK inhibitors, and immune checkpoint inhibition will be explored.

项目总结-项目3：自噬